Lantheus Holdings Inc (LNTH)

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ:...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Lantheus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

BEDFORD, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”...

Lantheus' LNTH-2513 (18F-GP1) PET/CT Awarded SNMMI’s Image of the Year

BEDFORD, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ: LNTH), the...

Form SD - Specialized disclosure report

Lantheus to Present at the William Blair 46th Annual Growth Stock Conference

BEDFORD, Mass., May 27, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”...

Lantheus Highlights New Radiodiagnostic Data at the 2026 SNMMI Annual Meeting

BEDFORD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the...

Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

BEDFORD, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]